20
https://pubmed.ncbi.nlm.nih.gov/38113661
The abstract reports a study finding that 10% of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICI) experienced durable long-term responses, with a low rate of relapse after ICI discontinuation, and that immune-related adverse events (irAEs), although common, were typically mild.
